VALCHLOR® (mechlorethamine) gel is an alkylating drug indicated for the topical treatment of Stage IA and IB mycosis fungoides–type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy

Stage IA/IB MF-CTCL is routinely managed by
qualified skin experts1

MF-CTCL is a difficult to diagnose, slowly progressing form of cancer that appears on skin1-3

Patients can present with different symptoms that resemble other inflammatory skin conditions.3

Example of Stage IA/IB MF-CTCL as Patches


Example of Stage IA/IB MF-CTCL as Plaques


Example of Stage IA/IB MF-CTCL as Hypopigmentation


Actual Stage IA/IB MF-CTCL patient examples.

Man (not an actual patient)

Key risk factors for MF-CTCL

Common patient characteristics (not limited to)2:

Age: 55 to 60 years

Gender: Male

Race: African-American

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommendations for diagnosis4

  • Biopsy of suspicious skin sites
  • Review of slides by pathologist with expertise in the diagnosis of CTCLs
  • Immunohistochemistry panel of skin biopsy
  • Molecular analysis to detect clonal T-cell antigen receptor (TCR) gene rearrangements or other assessment of clonality